The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis

1

Angiogenesis inhibitors combined with chemotherapy significantly improve progression-free survival (PFS) in advanced breast cancer but do not enhance overall survival (OS).
2

The meta-analysis included 29 RCTs with 11,068 patients, showing improved objective response rates and clinical benefit rates with the addition of angiogenesis inhibitors.
3

Monoclonal antibodies (mAbs) like bevacizumab are more effective in triple-negative breast cancer (TNBC), while tyrosine kinase inhibitors (TKIs) show better trends in hormone receptor-positive diseas
4

Increased safety risks, including hypertension and proteinuria, were associated with the use of angiogenesis inhibitors, necessitating proactive management of these toxicities.
5

The findings underscore the need for optimal patient selection and further research to clarify the comparative efficacy of different angiogenesis inhibitors in advanced breast cancer.

1